You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK):達伯舒新增三項一線適應症納入國家醫保目錄
阿思達克 12-03 12:07
信達生物(01801.HK)公佈,根據國家醫療保障局的最新公告,集團與禮來共同開發的創新PD-1抑制劑達伯舒已獲批所有適應症成功納入新版國家醫保目錄乙類範圍,將於2022年1月1日起正式實施。 本次達伯舒已獲批所有四項適應症均成功納入新版國家醫保目錄,其中三大適應症首次納入醫保目錄, 包括用於未經系統治療的表皮生長因數受體基因突變陰性和間變性淋巴瘤激(酉每)陰性的晚期或複發性非鱗狀非小細胞肺癌的一線治療;用於不可手術切除的晚期或複發性鱗狀非小細胞肺癌的一線治療;用於既往未接受過系統治療的不可切除或轉移性肝細胞癌的一線治療。 另外,達伯舒用於至少經過二線系統化療的復發或難治性經典型霍奇金淋巴瘤的適應症「cHL」於2019年首次納入國家醫保目錄,今年成功續約。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account